| Document and Entity Information | Aug. 10, 2022 |
| Cover [Abstract] | |
| Amendment Flag | false |
| Entity Central Index Key | 0001656536 |
| Document Type | 8-K |
| Document Period End Date | Aug. 10, 2022 |
| Entity Registrant Name | Decibel Therapeutics, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-40030 |
| Entity Tax Identification Number | 46-4198709 |
| Entity Address, Address Line One | 1325 Boylston Street |
| Entity Address, Address Line Two | Suite 500 |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02215 |
| City Area Code | (617) |
| Local Phone Number | 370-8701 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common stock, $0.001 par value per share |
| Trading Symbol | DBTX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
